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Summary  Vasospastic  angina  is  a  frequent  and  well-recognized  pathology  with  a  high  risk  of
life-threatening  ventricular  arrhythmias  and  sudden  cardiac  death.  The  diagnosis  of  vasospastic
angina requires  the  combination  of  clinical  and  electrocardiographic  variables  and  the  resultsdeﬁbrillator; of provocation  tests,  such  as  ergonovine  administration.  Smoking  cessation  is  the  ﬁrst  step
Sudden  cardiac
death;
Ventricular
arrhythmia
in the  management  of  vasospastic  angina.  Optimal  medical  treatment  using  calcium-channel
blockers and/or  nitrate  derivatives  can  provide  protection,  but  life-threatening  ventricular
arrhythmias  may  occur  despite  optimal  medical  treatment  and  several  years  after  the  start  of
treatment.  In  this  review,  we  evaluate  the  role  of  implantable  deﬁbrillators  as  a  complement  to
Abbreviations: CAS, coronary artery spasm; ICD, implantable cardioverter deﬁbrillator; LTVA, life-threatening ventricular arrhythmia;
ACE, major adverse cardiac events; SCD, sudden cardiac death; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
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optimal  medical  management  in  patients  with  life-threatening  ventricular  arrhythmias  due  to
vasospastic angina;  this  role  is  not  well  characterized  in  the  literature  or  guidelines.  We  discuss
the role  of  implantable  deﬁbrillators  in  secondary  prevention  in  light  of  three  recent  cases
managed  in  our  departments  and  a  review  of  the  literature.  An  implantable  deﬁbrillator  was
implanted in  two  of  the  three  cases  of  vasospastic  angina  with  ventricular  arrhythmias  that  we
managed.  We  considered  secondary  prevention  by  implantable  deﬁbrillator  to  be  justiﬁed  even
in the  absence  of  any  obvious  risk  factor.  Ventricular  arrhythmias  recurred  during  implantable
deﬁbrillator  follow-up  in  the  two  patients  implanted.
Conclusion.  —  In  patients  with  life-threatening  ventricular  arrhythmias  due  to  vasospastic
angina, an  implantable  deﬁbrillator  should  be  considered  because  of  the  risk  of  recurrence
despite optimal  medical  management.
©  2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’angor  spastique  est  une  pathologie  fréquente  et  connue  de  longue  date  ayant
une morbimortalité  non-négligeable.  Il  existe  notamment  un  risque  important  de  mort  subite.
Le diagnostic  repose  sur  l’association  de  signes  cliniques,  électrocardiographiques  et  par  la
conﬁrmation  diagnostic  par  un  test  de  provocation  au  méthergin.  L’arrêt  du  tabagisme  est
le point  essentiel  du  traitement.  Il  est  associé  à  un  traitement  médicamenteux  anti-spastique
composé  d’inhibiteurs  calciques  et/ou  de  dérivés  nitrés.  Malheureusement  cette  prise  en  charge
est insufﬁsante  et  le  risque  de  mort  subite  reste  présent  durant  plusieurs  années  après  que  le
diagnostic  ait  été  porté.  Dans  cette  revue,  nous  évaluons  la  place  du  déﬁbrillateur  automatique
implantable  en  sus  du  traitement  médicamenteux  chez  des  patients  ayant  présenté  une  mort
subite récupérée  suite  à  un  spasme  coronaire  dont  la  place  reste  ﬂoue.
Méthodes.  —  Nous  discutons  cette  place  à  la  lumière  de  trois  cas  que  nous  avons  pris  en  charge
et d’une  revue  complète  de  la  littérature.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Vasospastic  angina  is  one  of  the  most  important  functional
abnormalities  of  the  coronary  artery  with  a  high  risk  of  mor-
bidity  (myocardial  infarction)  and  mortality  [1,2]  (sudden
cardiac  death  [SCD]  from  severe  life-threatening  ventricular
arrhythmias  [LTVAs]  [3,4]).  Vasospastic  angina  accounts  for
5%  of  cases  of  cardiac  arrest  from  severe  ventricular  arrhyth-
mias.  Printzmetal  et  al.  ﬁrst  described  vasospastic  angina  in
1959  [5].  Diagnosis  remains  difﬁcult  and  is  based  on  com-
bined  evidence,  especially  as  coronary  artery  spasm  (CAS)
can  occur  in  the  absence  of  any  chest  pain  [6—8]. Per-critical
electrocardiographical  signs  are  highly  suggestive,  but  diag-
nosis  is  usually  conﬁrmed  by  spasm-provocation  tests  during
coronary  angiography  [9],  with  ergonovine  or  acetylcholine
administration  [10].
Endothelial  dysfunction  associated  with  loss  of  nitric
oxide  secretion  remains  the  main  physiopathological  fac-
tor  implicated  in  vasospastic  angina  [11,12],  but  other
pathways  are  being  explored  [13]  without  any  effective
alternative  treatments.  Currently,  calcium-channel  blockers
usually  bring  the  spastic  angina  under  control  and  ensure
a  good  long-term  prognosis  [14],  without,  however,  provid-
ing  optimal  efﬁcacy  in  all  patients.  Furthermore,  patients
with  vasospastic  angina  who  survive  LTVAs  are  a  partic-
ularly  high-risk  population  [15].  As  medical  management
is  not  completely  effective,  an  implantable  cardioverter
deﬁbrillator  (ICD)  may  offer  a  complementary  management
strategy,  particularly  in  the  secondary  prevention  of  LTVAs
due  to  vasospastic  angina.
b
ﬁ
o
oWe  discuss  the  role  of  ICDs  in  the  secondary  prevention
f  SCD  from  severe  LTVAs  due  to  vasospastic  angina  in  light
f  three  recent  cases  managed  in  our  centre  and  a  review
f  the  literature.
ase studies
irst case
 52-year-old  female  smoker  was  admitted  for  a  ﬁrst
on-ST-segment  elevation  myocardial  infarction  with  angio-
raphically  healthy  coronary  arteries.  She  was  discharged
n  isosorbide  mononitrate  (40  mg/day),  a  calcium-channel
locker  (verapamil,  120  mg  twice  daily),  a  statin  (atorvas-
atin,  80  mg/day)  and  aspirin  (160  mg/day).
Six  months  later,  the  patient  was  hospitalized  for  a  car-
iac  arrest;  she  received  early  resuscitation  manoeuvres
nd  two  shocks  delivered  by  a  semiautomatic  deﬁbrilla-
or  for  ventricular  ﬁbrillation  (VF).  The  post-resuscitation
lectrocardiogram  showed  alternation  between  normal
epolarization  and  a  pathognomic  pattern  of  Prinzmetal’s
ngina  (Fig.  1A  and  B).  Emergency  coronary  angiogra-
hy  showed  a  diffuse  —  nearly  occlusive  —  spasm  of  the
ntire  coronary  tree  (Fig.  2A:  circumﬂex  and  left  anterior
escending  arteries  >  90%  spastic  occlusion),  relieved  only
y  intracoronary  isosorbide  dinitrate  injection  (which  con-
rmed  the  diagnosis  of  vasospastic  angina:  the  combination
f  the  presence  of  a  >  90%  transient  occlusion  of  at  least
ne  coronary  artery  with  signs/symptoms  of  myocardial
44  R.  Eschalier  et  al.
Figure 1. Electrocardiogram changes due to vasospastic angina. A. Electrocardiogram with pathognomic pattern of Prinzmetal’s angina
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en inferior leads (arrows) and signs of ventricular excitability (as
lectrocardiogram a few minutes later after intravenous administrat
schaemia  and  a  positive  drug  induction  test  by  intracoronary
sosorbide  dinitrate).  The  coronary  arteries  were  angio-
raphically  healthy  after  this  injection  (Fig.  2B).
Given  the  recurrence  of  symptoms  and  LTVAs  due  to
asospastic  angina  under  optimal  medical  treatment,  we
ecided  to  implant  an  ICD  and  the  patient  was  discharged
ith  amlodipine  (10  mg/day),  nicorandil  (10  mg/day),
ifedipine  (30  mg/day),  atorvastatin  (80  mg/day)  and  dou-
le  antiplatelet  therapy  because  of  acute  coronary
yndrome  due  to  CAS  (aspirin  [100  mg/day]  and  clopidogrel
75  mg/day]).
At  18-month  follow-up,  ICD  interrogation  showed  several
pisodes  of  ventricular  tachycardia  (VT),  with  a  maximum
uration  of  14  seconds,  which  is  too  short  for  the  ICD  to
reat.
econd case
 54-year-old  male  smoker  was  admitted  after  a  car-
iac  arrest  resuscitated  by  two  external  shocks  delivered
y  a  semiautomatic  deﬁbrillator  without  signs  of  car-
iogenic  shock.  The  post-resuscitation  electrocardiogram
howed  huge  T  waves  in  anterior  leads.  The  emergency
oronary  angiography  highlighted  a  spastic  proximal  left
D
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ak) after resuscitated sudden cardiac death. B. Normalization of
 isosorbide mononitrate, without signs of acute coronary syndrome.
nterior  descending  artery  associated  with  a mid  left
nterior  descending  artery  occlusion  with  an  aspect  of
hrombus  in  a  milking  portion  (Fig.  3A).  The  occlusion  was
elieved  by  thromboaspiration  and  implantation  of  a  bare-
etal  stent.  Evolution  was  favourable,  without  neurological
equelae  or  myocardial  damage  (no  echocardiographic  scar).
espite  combined  amiodarone  (200  mg/day)  and  bisopro-
ol  (10  mg/day)  treatment,  the  patient  exhibited  several
pisodes  of  sustained  VT.
We  decided  to  perform  a  second  coronary  angiography
 month  later  because  of  sustained  VT;  this  showed  occlu-
ive  spasm  (associated  with  chest  pain)  at  the  end  of  the  left
ain  coronary  artery,  relieved  by  intracoronary  isosorbide
ononitrate  administration,  without  any  signiﬁcant  steno-
is,  conﬁrmed  by  optical  coherence  tomography  imaging  (no
laque  rupture  or  coronary  artery  dissection)  (Fig.  3B).
The  initial  cardiocirculatory  arrest  was  retrospectively
ttributed  to  vasospastic  angina  of  the  proximal  left  ante-
ior  descending  artery  complicated  by  thrombosis  and
mbolism  in  the  mid  left  anterior  descending  artery.
espite  adapted  treatment  (nifedipine  [30  mg/day],  ver-
pamil  [240  mg/day],  atorvastatin  [80  mg/day],  ramipril
3.75  mg/day],  aspirin  [75  mg/day],  prasugrel  [10  mg/day]
nd  nicotine  in  a  patch  [35  mg/day]  with  cessation  of
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lFigure 2. Diffuse coronary artery spasm (A) before and (B) after
relief by administration of intracoronary isosorbide mononitrate.
smoking),  episodic  polymorphic  VT  continued  for  5  weeks.
We  ﬁnally  decided  to  implant  an  ICD  because  of  the  inef-
fectiveness  of  optimal  medical  treatment  in  controlling
spasticity  and  ventricular  arrhythmias.  An  ICD  check-up  at
18  months  found  persistent  non-sustained  episodes  of  VT,  not
requiring  ICD  treatment,  under  optimal  medical  treatment.Third case
A  56-year-old  male  ex-smoker,  who  had  started  smoking
again  1  week  previously,  complained  of  chest  pain  at  rest
o
m
n
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Figure 3. Angiocoronarography and optical coherence tomography. A
(arrow). B. Optical coherence tomography of left main descending arter45
ver  the  previous  24  hours.  The  most  recent  pain  attack  was
ollowed  by  a brief  loss  of  consciousness.
The  patient  was  admitted  to  our  intensive  care  unit.
linical  examination  was  normal.  A  resting  electrocar-
iogram  showed  negative  T  waves  in  anterior  leads.  A
oronary  angiography  via  a  right  femoral  approach  found
hin  non-signiﬁcant  atheroma  throughout  the  coronary  tree.
n  ergonovine  administration  test  (intravenous  injection  of
.4  mg  of  ergonovine)  induced  an  explosive  response,  with
id  left  anterior  descending  artery  occlusion  and  clinically
ymptomatic  onset  of  sustained  VT  (Fig.  4A  and  B).  Loss  of
onsciousness,  VT  and  angiographical  abnormalities  quickly
esolved  on  intracoronary  isosorbide  dinitrate  injection.  The
atient  was  discharged  with  verapamil  (240  mg/day),  aspirin
75  mg/day)  and  rosuvastatin  (10  mg/day),  without  recur-
ence  of  angina  symptoms.  As  symptoms  were  under  control
nd  treatment  compliance  and  deﬁnitive  cessation  of  smok-
ng  could  be  relied  upon,  no  ICD  was  implanted.  At  17-month
ollow-up,  the  patient  remained  symptom  free,  with  a  nor-
al  cardiological  examination.
iscussion
hese  three  cases,  along  with  many  previous  reports  [16],
how  the  difﬁculties  in  the  management  of  resuscitated
CD  induced  by  a  severe  LTVA  (VT  or  VF)  following  CAS.
t  present,  there  are  no  consistent  guidelines  to  help  clini-
ians  to  decide  whether  to  implant  an  ICD  in  such  patients.
CD  implantation  is  recommended  by  some  groups  [17]  but
dvised  against  by  others  [18]. In  this  discussion,  we  review
he  literature  and  seek  to  provide  management  advice.
Vasospastic  angina  is  a  severe  and  potentially  lethal
athology,  with  a  high  risk  of  SCD  from  severe  LTVAs  (VT
r  VF).  The  prognosis  of  vasospastic  angina  under  optimal
edical  treatment  is  quite  good  (98%  death-free  survival
nd  92%  major  adverse  cardiac  events  (MACE)-free  survival
cardiac  death,  non-fatal  MI,  hospitalization  due  to  unsta-
le  angina  pectoris  and  heart  failure]  at  5-year  follow-up)
10]. By  comparison,  the  prognosis  for  survivors  of  an  out-
f-hospital  cardiac  arrest  due  to  vasospastic  angina  is  still
oor  (72%  MACE-free  survival  at  5  years  [15]).  Moreover,  the
otential  risk  of  recurrence  is  underestimated  and  persists
ong  after  diagnosis  [19], because  of  the  loss  of  efﬁcacy
f  medical  treatment  and  the  long-term  discontinuation  in
any  patients.  The  severity  of  the  disease  depends  on  the
umber  of  arteries  affected  by  the  spasm:  a  diffuse  spasm
as  a poorer  prognosis  than  single  vessel  involvement  [20].
. Initial angiocoronarography with thombus in circumﬂex artery
y without signiﬁcant stenosis.
46  R.  Eschalier  et  al.
Figure 4. Images of vasospastic angina before and after
ergonovine administration. A. Initial angiocoronarography, left
coronary view, with non-signiﬁcant atheroma. B. Angiocoro-
narography, left coronary view, after ergonovine administration,
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Figure 5. Management cascade of life-threatening ventricular
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vention  of  resuscitated  SCD  from  severe  LTVAs  due  toighlighting a mid left anterior descending artery occlusion (arrow)
nd onset of ventricular tachycardia.
Medical  treatment  is  the  pivotal  part  of  the  management
trategy,  using  non-dihydropyridine  calcium-channel  block-
rs  [14]  and/or  nitrate  derivatives,  both  of  which  provide
roven  protection  against  recurrence.  Unfortunately,  this
reatment  is  insufﬁcient,  even  when  given  optimally,  and
t  fails  to  eliminate  all  risk  of  recurrence  of  vasospastic
ngina  and  hence  of  severe  LTVAs.  Cessation  of  smoking  is
andatory.  There  is  consensus  for  prescription  of  statins
nd  low-dose  aspirin,  but  beta-blockers,  as  vasoconstrictive
reatments,  are  classically  avoided  [21].
An  ICD  may  thus  not  be  indicated  in  primary  prevention  in
atients  without  spasm-related  SCD.  The  role  of  ICDs  in  sec-
ndary  prevention  after  resuscitated  SCD  due  to  vasospastic
ngina  is  unknown.
The  current  debate  is  whether  or  not  secondary  preven-
ion  by  an  ICD  should  concern  all  cases  of  recovery  from
CD  from  severe  LTVA  due  to  vasospastic  angina.  Risk  factors
hypothermia  [22],  ionic  disorder,  smoking,  drug  abuse  [23],
v
a
urrhythmias due to coronary artery spasm (CAS). ICD: implantable
ardioverter deﬁbrillator.
old  environment  [22], hypomagnesaemia  [24],  etc.)  and
omorbidities  should  be  assessed  before  an  ICD  is  proposed.
Another  issue  is  the  role  of  ergonovine  and  acetylcholine
rovocation  tests  [25]  for  prognostic  rather  than  diagnostic
urposes  [9]  in  these  patients:  mixed-type  multivessel  spasm
ad  a  signiﬁcant  prognostic  impact  on  vasospastic  angina
atients,  whereas  the  arrhythmic  complications  during  the
rovocation  tests  did  not  [10].
Therefore,  despite  the  above-mentioned  limitations,  we
onsidered  ICD  to  be  indicated  for  the  secondary  preven-
ion  of  SCD  from  severe  LTVA  due  to  CAS  in  two  of  our  three
atients,  in  line  with  opinions  defended  elsewhere  [26,27].
e  subsequently  designed  an  algorithm  to  help  our  depart-
ents  to  decide  whether  to  implant  an  ICD,  according  to  our
ecent  cases  and  a  review  of  the  literature  (Fig.  5).
tudy limitations
ur  study  population  is  limited  by  its  small  size.  Ideally,
arge  randomized  multicentre  trials  could  address  important
ssues  such  as  risk  stratiﬁcation,  primary/secondary  preven-
ion  and  outcome  of  ICD  therapy  in  this  population,  but  these
ssues  would,  however,  be  difﬁcult  to  assess.
onclusions
he  question  of  ICD  implantation  in  the  secondary  pre-asospastic  angina  remains  unanswered.  In  our  opinion,
rrhythmia  management  should  not  be  excluded.  The  fail-
re  and  complications  of  optimal  medical  control  led  us  to
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opt  for  secondary  prevention  by  ICD  implantation  in  LTVAs
due  to  vasospastic  angina.
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